{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:14:02Z","timestamp":1791951242792,"version":"4.3.4"},"reference-count":7,"publisher":"American Medical Association (AMA)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,4,6]]},"DOI":"10.1001\/jama.2021.3199","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T16:34:04Z","timestamp":1614357244000},"page":"1318","source":"Crossref","is-referenced-by-count":384,"title":["SARS-CoV-2 Vaccines"],"prefix":"10.1001","volume":"325","author":[{"given":"C. Buddy","family":"Creech","sequence":"first","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon C.","family":"Walker","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Samuels","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"jit210016r1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2014a target for vaccine and therapeutic development.","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol"},{"issue":"48","key":"jit210016r2","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci Immunol"},{"issue":"4","key":"jit210016r3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035421","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"jit210016r4","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination.","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"jit210016r6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors.","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther"},{"issue":"50","key":"jit210016r7","doi-asserted-by":"publisher","first-page":"e3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity.","volume":"109","author":"Zak","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"jit210016r5","unstructured":"Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. News release. January 28, 2021. Accessed February 21, 2021. https:\/\/ir.novavax.com\/news-releases\/news-release-details\/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2777059\/jama_creech_2021_it_210016_1617663050.86462.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T15:45:39Z","timestamp":1617723939000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2777059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":7,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,4,6]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.3199","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,6]]}}}